Zika virus vaccine in mice shows promising start
#Cosmoread: A new vaccine against Zika virus shows promising results in mice, a pharmaceutical company yesterday (Feb. 17) announced in a statement.
Commentary “strong and lasting immune response induced” in the mice, the vaccine manufacturer, Inovio Pharmaceuticals, said in a statement.
Researchers still have the mosquito Zika virus as a means to protect the people, vaccine, SynCon are working on is called. Only 1 in 5 people infected with the virus, symptoms, which include fever, rash and muscle pain can attend shows. However, Zika virus-infected pregnant women, children, the risk of microcephaly (small brain and head size) may increase, prompting a race to create a vaccine against the virus. Zika also Guillain-Barre syndrome, an autoimmune disorder that can be associated with.
Inovio Zika about a dozen companies are working on vaccines. Inovio vaccine detectable levels of specific antibodies in the blood of rats helped to develop, the company reported. In addition, the vaccine prompted “strong and broad T cell responses” that the Zika virus could fight, company representatives said.
Although the vaccine is still in animal testing, by the end of this year could be available for clinical trials in people.
“With strong antibodies and killer T cell responses generated by our vaccine in mice, nonhuman primates in the next start clinical vaccine trials and product must be produced,” Dr. J. Joseph Kim, Inovio’s president and CEO. “We have our Zika I vaccine before the end of 2016 and plans to initiate human testing phase”